

# SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\*

## 上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

(Stock code: 1877)

(股份代號: 1877)

### NOTIFICATION LETTER 通知信函

21 November 2019

Dear registered holder,

**Shanghai Junshi Biosciences Co., Ltd.\* (the “Company”)**

**Notice of Publication of Notice of the 2020 First Extraordinary General Meeting (“EGM”) (“Current Corporate Communication”)**

The English and Chinese versions of the Company’s Current Corporate Communication are available the websites of the Company (www.junshipharma.com) and The Stock Exchange of Hong Kong Limited (www.hkexnews.hk), or the arranged printed form(s) of Current Corporate Communication is enclosed (if applicable).

Shareholders may at any time choose to receive free of charge Corporate Communications<sup>(Note)</sup> either in printed form, or read the website version; and either in English language version only, Chinese language version only or both language versions, notwithstanding any wish to the contrary they have previously conveyed to the Company. If you want to receive another printed version of the Current Corporate Communication, please complete the Request Form printed on the reverse side and send it to the Company c/o Tricor Investor Services Limited (the “H Share Registrar”), using the mailing label and need not affix a stamp when returning (if posted in Hong Kong). Otherwise, please affix an appropriate stamp. The address of the H Share Registrar is Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong. The Request Form may also be downloaded from the Company’s website at www.junshipharma.com or the HKEXnews’s website at www.hkexnews.hk.

If you would like to change your choice of language or means of receipt of the Company’s Corporate Communication in future, please complete the Request Form printed on the reverse side and send it to H Share Registrar, using the mailing label and need not affix a stamp when returning (if posted in Hong Kong). Otherwise, please affix an appropriate stamp. You may also send an email with a scanned copy of the completed and signed Request Form to 1877-ecom@hk.tricorglobal.com. Even if you have chosen (or are deemed to have consented) to receive all future Corporate Communications via website version but for any reason you have difficulty in receiving or gaining access to the Current Corporate Communication, the Company will promptly upon your request send the Current Corporate Communication to you in printed form free of charge.

For those Shareholders who would like to appoint proxy(ies) to attend and vote in their stead at the EGM, please download the Proxy Form from the EGM from the Company’s or the HKEXnews’s website, and complete, sign and deposit the Proxy Form at the H Share Registrar following the instructions as provided in the Notes to the Proxy Form.

For those Shareholders who intend to attend the EGM in person or by proxy(ies), please download the Reply Slip for the EGM from the Company’s or the HKEXnews’s website, and complete, sign and return the Reply Slip to the Company or the H Share Registrar following the instructions as provided in the Notes to the Reply Slip.

Should you have any queries relating to this letter, please contact the H Share Registrar at (852) 2980 1333 during business hours from 9:00 a.m. to 5:00 p.m. from Monday to Friday, excluding Hong Kong public holidays.

Yours faithfully

By order of the Board

**Shanghai Junshi Biosciences Co., Ltd.\***

**Mr. Xiong Jun**

Chairman

*Note: Corporate Communications include but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form; and (g) a reply slip.*

\* For identification purposes only.

各位登記持有人：

上海君實生物醫藥科技股份有限公司（「本公司」）

2020年第一次臨時股東大會（「臨時股東大會」）通告（「是次公司通訊」）之發佈通知

本公司的是次公司通訊中、英文版本已上載於本公司網站(www.junshipharma.com)及香港聯合交易所有限公司披露易網站(www.hkexnews.hk)，歡迎瀏覽；或已按安排附上是次公司通訊之印刷本（如適用）。

儘管閣下早前曾向本公司作出公司通訊<sup>(附註)</sup>收取方式或語言版本的選擇，但仍可以隨時更改有關選擇，轉為以印刷本或網上方式收取及只收取英文印刷本、或只收取中文印刷本；或同時收取中、英文印刷本，費用全免。如閣下欲收取是次公司通訊之另一語言印刷本，請閣下填妥在本函背面的申請表格，並使用隨附之郵寄標籤寄回本公司之H股股份過戶登記處卓佳證券登記有限公司（「H股股份過戶登記處」），而毋須貼上郵票（如在香港投寄）；否則，請貼上適當的郵票。H股股份過戶登記處的地址為香港皇后大道東183號合和中心54樓。申請表格亦可於本公司網站(www.junshipharma.com)或披露易網站(www.hkexnews.hk)內下載。

如日後欲選擇有別於閣下所選擇的公司通訊語言版本或收取方式，請填妥在本函背面的申請表格，並使用隨附之郵寄標籤寄回H股股份過戶登記處，而毋須貼上郵票（如在香港投寄）；否則，請貼上適當的郵票。閣下亦可把已填妥及簽署之申請表格的掃描副本電郵至1877-ecom@hk.tricorglobal.com。如股東已選擇以網上方式收取日後公司通訊（或被視為已同意以網上方式收取）但因任何理由未能閱覽載於網站的是次公司通訊，股東只要提出要求，本公司將盡快向閣下寄上所要求的有關文件的印刷版本，費用全免。

股東如欲委任代表出席臨時股東大會及於會上代為投票，請於本公司或披露易網站下載臨時股東大會代表委任表格，並根據代表委任表格內附註之指示填寫、簽署，及將代表委任表格送達H股股份過戶登記處。

股東如欲親身或委任代表出席臨時股東大會，請於本公司或披露易網站下載臨時股東大會回執，並根據回執內附註之指示填寫、簽署，及將回執送達本公司或H股股份過戶登記處。

倘閣下對本函內容有任何疑問，請於辦公時間內，即星期一至星期五（香港公眾假期除外）上午9時正至下午5時正致電H股股份過戶登記處之電話熱線(852) 2980 1333查詢。

此致

董事會會同

上海君實生物醫藥科技股份有限公司

主席

熊俊先生

謹啟

2019年11月21日

附註：公司通訊包括但不限於：(a)董事會報告、年度賬目連同核數師報告及財務摘要報告（如適用）；(b)中期報告及中期摘要報告（如適用）；(c)會議通告；(d)上市文件；(e)通函；(f)代表委任表格；及(g)回執。

\* 僅供識別之用

**Shareholder's information (Full name and address)**  
**股東資料 (全名及地址)**

## REQUEST FORM 申請表格

To: **Shanghai Junshi Biosciences Co., Ltd.\* (the “Company”)**  
**(Stock Code: 1877)**  
 c/o Tricor Investor Services Limited  
 Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong

致： 上海君實生物醫藥科技股份有限公司（「本公司」）  
（股份代號：1877）  
經卓佳證券登記有限公司  
香港皇后大道東183號合和中心54樓

I/We have already received a printed copy of the Current Corporate Communication in Chinese/English or have chosen (or are deemed to have consented) to read the Current Corporate Communication posted on the Company's website:  
本人／我們已收取是次公司通訊之中文／英文印刷本或已選擇（或被視為已同意）瀏覽本公司網站所登載之是次公司通訊：

**Part A** I/We would like to receive a printed version of the Current Corporate Communication of the Company as indicated below:  
**甲部** 本人／我們現希望以下列方式收取 貴公司最近公司通訊之語言印刷本：

(Please mark a "✓" in **ONLY ONE** of the following boxes)  
(請從下列選擇中，僅在其中一個空格內劃上「✓」號)

☐ I/We would like to receive a **printed copy in English.**  
本人／我們希望收取一份英文印刷本。

☐ I/We would like to receive a **printed copy in Chinese**  
本人／我們希望收取一份中文印刷本。

☐ I/We would like to receive both the printed English and Chinese copies.  
本人／我們希望收取英文和中文各一份印刷本。

**Part B** I/We would like to change the choice of language(s) and/or means of receipt of future Corporate Communications\* of the Company as indicated below:  
**乙部** 本人／我們現希望更改以下列方式收取 貴公司今後公司通訊\*之語言版本及／或收取方式：

(Please mark a "✓" in **ONLY ONE** of the following boxes)  
(請從下列選擇中，**僅**在其中一個空格內劃上「✓」號)

☐ to access all future Corporate Communications by **electronic means** through the Company's website instead of receiving printed copies, and receive an email notification to my/our email address below or a notification letter of the publication of the Corporate Communications on the Company's website; **OR**  
 透過本公司網站以 **電子方式** 瀏覽所有日後公司通訊以代替收取印刷本, 並向本人 / 我們發出電郵通知 (本人 / 我們之電郵地址如下) 或就於本公司網站刊登公司通訊發出通知信函; 或

[illegible]

(Please provide the email address in English Capital Letters and the email address will be used for email notification of the release of the Corporate Communications only. If no email address is provided, a printed notification letter of the posting of Corporate Communications on the website of the Company will be sent to you by post at your address as appearing in the Company's register of members.)

(請以英文正楷填寫電郵地址，有關電郵地址將僅用作收取公司通訊已發佈之電郵通知。如未有提供電郵地址，我們將透過郵寄方式，按閣下於本公司的股東名冊上所示之地址向閣下寄發有關公司通訊於本公司網站登載之通知信函之印刷本。)

☐ to receive the **printed English version** of all future Corporate Communications ONLY; OR  
僅收取所有日後公司通訊的英文印刷本；或

to receive the **printed Chinese version** of all future Corporate Communications ONLY; OR  
僅收取所有日後公司通訊的中文印刷本；或

☐ to receive both the **printed English and Chinese versions** of all future Corporate Communications.  
同時收取所有日後公司通訊的英文及中文印副本。

Shareholder's full name 股東全名：

Signature 簽名：

(Please use **BLOCK LETTERS** 請用正楷填寫)

Address 地址：

Contact telephone number 聯絡電話號碼：

Date 日期：

*Notes 附註：*

1. Please complete all your details clearly.  
請 閣下清楚填妥所有資料。
2. If your shares are registered in joint names, the shareholder whose name stands first on the register of members of the Company in respect of the joint holding should sign on this Request Form in order to be valid.  
如屬聯名股東，則本申請表格須由該名於本公司股東名冊上就聯名持有股份姓名首位的股東簽署，方為有效。
3. Any form with more than one box marked (✓), with no box marked (✓), with no signature or otherwise incorrectly completed will be void.  
任何表格有超過一個填滿「✓」，或沒有填滿「✓」，或沒有簽署，或沒有正確填妥，或沒有填妥任何填滿「✓」的資料，則本表格將無效。
4. The above instruction will apply to the current and all future Corporate Communications to be sent to you until you notify to the Company c/o Tricor Investor Services Limited to the contrary or unless you have at anytime ceased to hold the shares in the Company.  
上述指示適用於發送予 閣下之是次及所有日後本公司之招股說明書及所有其他公司通訊，直至 閣下通知本公司之招股說明書及所有其他公司通訊之發送或任何時候停止持有本公司的股份。
5. For the avoidance of doubt, the Company does not accept any special instructions written on this Request Form.  
為免有疑，任何在本申請表格上的額外指示將不被本公司所予處理。
6. Communications include (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form; and (g) a reply slip.  
公司通訊包括但不限於：(a)董事會報告、年度賬目連同核數師報告及財務摘要報告（如適用）；(b)中期報告及中期摘要報告（如適用）；(c)會議通告；(d)上市文件；(e)通函；(f)代表委任表格；及(g)回執。



*Please cut the mailing label and stick it on an envelope to return this Reply Form to us.*

*No postage stamp is necessary if posted in Hong Kong.*

閣下寄回此回條時，請將郵寄標籤剪貼於信封上。

如在香港投寄，毋須貼上郵票。



## MAILING LABEL 郵寄標籤

**Tricor Investor Services Limited**  
**Freepost No. 37**  
**Hong Kong**  
**卓佳證券登記有限公司**  
**簡便回郵號碼37**  
**香港**